Evidence map›Paper›PMID 28405508›Full record

ArticleOncoimmunology

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Yasmine Van Caeneghem, Stijn De Munter, Paola Tieppo, Glenn Goetgeluk, Karin Weening, Greet Verstichel, Sarah Bonte, Tom Taghon, Georges Leclercq, Tessa Kerre and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Mucosal-associated invariant T cells for cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  7. Article
  8. Donor T cells for CAR T cell therapy.Biomarker research · 2022
    Review
  9. Review
  10. Article
  11. Oncoimmunology · 2021
    Article
  12. The human fetal thymus generates invariant effector γδ T cells.The Journal of experimental medicine · 2020
    Article
  13. Review
  14. Article
  15. Article
  16. Approaches for generation of anti-leukemia specific T cells.Cell regeneration (London, England) · 2018
    Review
  17. Article
  18. Nanobody Based Dual Specific CARs.International journal of molecular sciences · 2018
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Yasmine Van CaeneghemDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Stijn De MunterDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Paola TieppoDepartment of Biopharmacy and Institute for Medical Immunology, Université Libre de Bruxelles (ULB) , Brussels, Belgium.
Glenn GoetgelukDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Karin WeeningDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Greet VerstichelDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Sarah BonteDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Tom TaghonDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Georges LeclercqDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Tessa KerreDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Reno DebetsLaboratory of Tumor Immunology, Department of Medical Immunology, Erasmus MC Cancer Center , Rotterdam, the Netherlands.
David VermijlenDepartment of Biopharmacy and Institute for Medical Immunology, Université Libre de Bruxelles (ULB) , Brussels, Belgium.
Hinrich AbkenCenter for Molecular Medicine Cologne (CMMC) and Department of Internal Medicine, University of Cologne , Cologne, Germany.
Bart VandekerckhoveDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University , Ghent, Belgium.
Ghent University · BEUniversité Libre de Bruxelles · BEErasmus MC Cancer Institute · NLUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical studies indicate that adoptive T-cell therapy and especially chimeric antigen receptor (CAR) T-cell therapy is a very potent and potentially curative treatment for B-lineage hematologic malignancies. Currently, autologous peripheral blood T cells are used for adoptive T-cell therapy. Adoptive T cells derived from healthy allogeneic donors may have several advantages; however, the expected occurrence of graft versus host disease (GvHD) as a consequence of the diverse allogeneic T-cell receptor (TCR) repertoire expressed by these cells compromises this approach. Here, we generated T cells from cord blood hematopoietic progenitor cells (HPCs) that were transduced to express an antigen receptor (AR): either a CAR or a TCR with or without built-in CD28 co-stimulatory domains. These AR-transgenic HPCs were culture-expanded on an OP9-DL1 feeder layer and subsequently differentiated to CD5

Indexed as

Chimeric antigen receptorcord bloodhematopoietic precursor cellhematopoietic stem cellimmunotherapyT cell

Identifiers

PMID28405508
PMCPMC5384408
OpenAlexW2577046495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.